PropertyValue
?:abstract
  • Common clinical features of patients with Coronavirus disease-2019 (COVID-19) vary from fever, to acute severe respiratory distress syndrome. Several laboratory parameters are reported as indicators of COVID-19 severity. We hereby describe the possible novel severity biomarkers for COVID-19, CD11b+CD33+HLA-DR-CD14+ cells and CD11b+CD33+HLA-DR-CD66b+ cells.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.3389/fmed.2020.580677
?:journal
  • Front_Med_(Lausanne)
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/c22b301c96d4d0b32cfbbd47179ca1df87e27d4a.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7592395.xml.json
?:pmcid
?:pmid
?:pmid
  • 33178720.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
?:type
?:year
  • 2020-10-14

Metadata

Anon_0  
expand all